An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Completed
- Conditions
- Colorectal Cancer
- Registration Number
- NCT01609075
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This observational, multicenter, retrospective/prospective study will evaluate the use of Avastin (bevacizumab) in clinical practice in patients with metastatic colorectal cancer. Patients having initiated first-line treatment with a fluoropyrimidine-based chemotherapy and Avastin will be followed for up to 15 months.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 437
Inclusion Criteria
- Adult patients, >/= 18 years of age
- Metastatic colorectal cancer
- Having initiated first-line treatment with fluoropyrimidine-based chemotherapy plus Avastin between 1. September 2011 and 29. February 2012
- Availability of test fro K-RAS genotyping
Exclusion Criteria
- Participation in a clinical trial during treatment with Avastin
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Proportion of patients with Avastin treatment discontinuation due to either disease progression or Avastin-related adverse events approximately 15 months
- Secondary Outcome Measures
Name Time Method Proportion of patients with treatment discontinuation due to other causes approximately 15 months Incidence of other causes for treatment discontinuation approximately 15 months Second-line treatments initiated approximately 15 months Progression-free survival (patients with treatment discontinuation due to disease progression or Avastin-related toxicity as compared to patients with treatment discontinuation due to other causes) approximately 15 months
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of bevacizumab in metastatic colorectal cancer treatment?
How does bevacizumab compare to other anti-VEGF therapies in mCRC clinical outcomes?
Which biomarkers correlate with bevacizumab response in Italian mCRC patient cohorts?
What adverse events are associated with bevacizumab in combination chemotherapy for mCRC?
Are there alternative anti-angiogenic agents showing improved efficacy over bevacizumab in mCRC?